. Schuliga M, et al. Am J Physiol Lung Cell Mol Physiol. 2021 Sep 15. doi: 10.1152/ajplung.00574.2020. Online ahead of print. Am J Physiol Lung Cell Mol Physiol. 2021. PMID: 34524912
.
. JAMA. 2021 Sep 8. doi: 10.1001/jama.2021.15494. Online ahead of print. JAMA. 2021. PMID: 34495304 No abstract available.
.
Item in Clipboard
.
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, Piruzeli MLB, Goldman JD, Alatorre-Alexander J, de Cassia Pellegrini R, Estrada V, Som M, Cardoso A, Chakladar S, Crowe B, Reis P, Zhang X, Adams DH, Ely EW; COV-BARRIER Study Group.
.
- Gluten intolerance a significant risk factor
- Infectious disease of the uterus
- Absence of an individual specific disease